vs
Aardvark Therapeutics, Inc.（AARD）与Arbutus Biopharma Corp（ABUS）财务数据对比。点击上方公司名可切换其他公司
Aardvark Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对炎症、代谢类疾病及罕见病的新型靶向疗法，核心管线聚焦G蛋白偶联受体相关药物，主要服务北美及全球患者群体，开展医药研发领域合作。
Arbutus生物制药是一家公开上市的加拿大生物制药企业，专长于脂质体药物递送与RNA干扰技术，目前主要开展针对乙型肝炎感染的治疗药物研发工作，在抗病毒新药研发领域拥有深厚的技术积累。
AARD vs ABUS — 直观对比
营收规模更大
ABUS
是对方的Infinity倍
$0
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $0 | $1.1M |
| 净利润 | $-17.6M | — |
| 毛利率 | — | — |
| 营业利润率 | — | -503.3% |
| 净利率 | — | — |
| 营收同比 | — | -33.2% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.81 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AARDABUS
| Q4 25 | $0 | $1.1M | ||
| Q3 25 | $0 | $529.0K | ||
| Q2 25 | $0 | $10.7M | ||
| Q1 25 | $0 | $1.8M | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | — | $1.3M | ||
| Q2 24 | — | $1.7M | ||
| Q1 24 | — | $1.5M |
净利润AARDABUS
| Q4 25 | $-17.6M | — | ||
| Q3 25 | $-16.3M | $-7.7M | ||
| Q2 25 | $-14.4M | $2.5M | ||
| Q1 25 | $-9.3M | $-24.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-19.7M | ||
| Q2 24 | — | $-19.8M | ||
| Q1 24 | — | $-17.9M |
营业利润率AARDABUS
| Q4 25 | — | -503.3% | ||
| Q3 25 | — | -1636.9% | ||
| Q2 25 | — | 13.9% | ||
| Q1 25 | — | -1456.9% | ||
| Q4 24 | — | -885.2% | ||
| Q3 24 | — | -1601.2% | ||
| Q2 24 | — | -1250.5% | ||
| Q1 24 | — | -1263.9% |
净利率AARDABUS
| Q4 25 | — | — | ||
| Q3 25 | — | -1463.5% | ||
| Q2 25 | — | 23.5% | ||
| Q1 25 | — | -1390.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1472.5% | ||
| Q2 24 | — | -1146.9% | ||
| Q1 24 | — | -1166.8% |
每股收益（稀释后）AARDABUS
| Q4 25 | $-0.81 | $-0.01 | ||
| Q3 25 | $-0.75 | $-0.04 | ||
| Q2 25 | $-0.66 | $0.01 | ||
| Q1 25 | $-0.71 | $-0.13 | ||
| Q4 24 | — | $-0.07 | ||
| Q3 24 | — | $-0.10 | ||
| Q2 24 | — | $-0.11 | ||
| Q1 24 | — | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $110.0M | $91.5M |
| 总债务越低越好 | — | $0 |
| 股东权益账面价值 | $106.6M | $76.6M |
| 总资产 | $117.2M | $94.6M |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资AARDABUS
| Q4 25 | $110.0M | $91.5M | ||
| Q3 25 | $126.3M | $22.4M | ||
| Q2 25 | $141.8M | $37.4M | ||
| Q1 25 | $151.3M | $37.1M | ||
| Q4 24 | — | $122.6M | ||
| Q3 24 | — | $31.8M | ||
| Q2 24 | — | $62.8M | ||
| Q1 24 | — | $43.1M |
总债务AARDABUS
| Q4 25 | — | $0 | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
股东权益AARDABUS
| Q4 25 | $106.6M | $76.6M | ||
| Q3 25 | $122.4M | $77.4M | ||
| Q2 25 | $136.9M | $83.0M | ||
| Q1 25 | $150.7M | $79.2M | ||
| Q4 24 | — | $97.4M | ||
| Q3 24 | — | $106.9M | ||
| Q2 24 | — | $122.5M | ||
| Q1 24 | — | $114.6M |
总资产AARDABUS
| Q4 25 | $117.2M | $94.6M | ||
| Q3 25 | $133.2M | $97.7M | ||
| Q2 25 | $147.5M | $103.3M | ||
| Q1 25 | $157.0M | $117.0M | ||
| Q4 24 | — | $131.7M | ||
| Q3 24 | — | $140.4M | ||
| Q2 24 | — | $160.0M | ||
| Q1 24 | — | $150.3M |
负债/权益比AARDABUS
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-16.8M | $-4.7M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AARDABUS
| Q4 25 | $-16.8M | $-4.7M | ||
| Q3 25 | $-16.1M | $-5.8M | ||
| Q2 25 | $-9.8M | $-15.7M | ||
| Q1 25 | $-11.4M | $-13.4M | ||
| Q4 24 | — | $-10.3M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | — | $-14.5M | ||
| Q1 24 | — | $-19.3M |
自由现金流AARDABUS
| Q4 25 | — | — | ||
| Q3 25 | $-16.1M | — | ||
| Q2 25 | $-9.9M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-10.4M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-14.5M | ||
| Q1 24 | — | $-19.4M |
自由现金流率AARDABUS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -660.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -840.4% | ||
| Q1 24 | — | -1265.7% |
资本支出强度AARDABUS
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 5.5% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 6.2% |
现金转化率AARDABUS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -6.24× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
